XNAS · Healthcare · Biotechnology
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | 0.17 | 0.17 | +0.00% | $12.3M | ➖ Inline | +0.00% | -0.50% | — |
| 2026-03-18 | Q4 2025 | -0.13 | 0.26 | +300.00% | $13.8M | ✅ Beat | +5.56% | +10.42% | +45.19% |
| 2025-11-12 |
| Q3 2025 |
| -0.01 |
| -0.29 |
| -2800.00% |
| $9.4M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.14 | 0.44 | +414.29% | $13.1M | ✅ Beat | +5.38% | +5.08% | +21.14% |
| 2025-05-13 | Q1 2025 | -0.29 | 0.06 | +120.69% | $15.9M | ✅ Beat | — | — | — |
| 2025-03-17 | Q4 2024 | -0.30 | -0.45 | -50.00% | $8.7M | ❌ Miss | — | — | — |
| 2024-11-07 | Q3 2024 | -0.44 | -0.39 | +11.36% | $7.2M | ✅ Beat | — | — | — |
| 2024-08-13 | Q2 2024 | -0.27 | -0.28 | -3.70% | $11.1M | ❌ Miss | — | — | — |
Showing last 8 quarters.